Table 3.
Univariate analyses for patients with ESCC.
| 5-year CSS (%) | P value | HR (95% CI) | P value | |
|---|---|---|---|---|
| Age (years) | 0.978 | 0.978 | ||
| ≤60 | 30.1 | 1.000 | ||
| >60 | 33.6 | 0.996 (0.762–1.302) | ||
| Gender | 0.322 | 0.327 | ||
| Female | 38.1 | 1.000 | ||
| Male | 30.6 | 1.227 (0.815–1.848) | ||
| Tumor length (cm) | 0.003 | 0.004 | ||
| ≤3 | 41.6 | 1.000 | ||
| >3 | 27.8 | 1.580 (1.157–2.157) | ||
| Tumor location | 0.556 | 0.564 | ||
| Upper | 41.2 | 1.000 | ||
| Middle | 33.1 | 0.735 (0.385–1.404) | 0.351 | |
| Lower | 29.0 | 0.908 (0.693–1.190) | 0.483 | |
| Differentiation | 0.198 | 0.207 | ||
| Good | 38.6 | 1.000 | ||
| Moderate | 31.0 | 1.185 (0.786–1.786) | 0.417 | |
| Poor | 28.6 | 1.504 (0.933–2.424) | 0.098 | |
| Vessel involvement | 0.007 | 0.008 | ||
| Negative | 34.1 | 1.000 | ||
| Positive | 18.9 | 1.577 (1.129–2.202) | ||
| Perineural invasion | 0.005 | 0.006 | ||
| Negative | 35.0 | 1.000 | ||
| Positive | 17.5 | 1.551 (1.135–2.119) | ||
| TNM stage | <0.001 | <0.001 | ||
| I | 51.9 | 1.000 | ||
| II | 32.7 | 1.878 (1.269–2.780) | 0.002 | |
| III | 18.8 | 2.943 (2.039–4.248) | <0.001 | |
| I stage | <0.001 | <0.001 | ||
| I0 | 50.0 | 1.000 | ||
| I1 | 30.9 | 1.696 (1.189–2.420) | 0.004 | |
| I2 | 18.2 | 2.676 (1.837–3.900) | <0.001 | |
| I3 | 8.3 | 4.372 (2.924–6.536) | <0.001 | |
| Adjuvant therapy | 0.398 | 0.402 | ||
| No | 32.0 | 1.000 | ||
| Yes | 30.6 | 1.130 (0.849–1.504) | ||
| CRP (mg/L) | <0.001 | <0.001 | ||
| ≤10.0 | 39.2 | 1.000 | ||
| >10.0 | 17.1 | 2.217 (1.692–2.906) | ||
| NLR | <0.001 | <0.001 | ||
| ≤3.5 | 39.0 | 1.000 | ||
| >3.5 | 17.7 | 1.925 (1.471–2.519) | ||
| PLR | <0.001 | <0.001 | ||
| ≤150 | 43.9 | 1.000 | ||
| >150 | 17.3 | 2.260 (1.729–2.955) |